HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

HIMS), recently made an interesting announcement. The healthcare company said that it will now offer branded Zepbound, Eli Lilly’s (NYSE: LLY) blockbuster weight loss drug. Zepbound is the most ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Personally, I've been on Zepbound for nearly 10 weeks now and I ... professional online is available in some states through Hims and Hers for men and women. Struggling with spring allergies?

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Hims & Hers Health HIMS, recently made an interesting announcement. The healthcare company said that it will now offer branded Zepbound, Eli Lilly’s LLY blockbuster weight loss drug. Zepbound is ...

In a short but sweet press release, Eli Lilly greatly diminished the enthusiasm that Zepbound would drive growth for Hims. It stated simply that “Eli Lilly and Company (NYSE:LLY) has no ...